APA (7th ed.) Citation

Arnaud, L., Mosca, M., Askanase, A., Strand, V., Banerjee, S., Singhal, S., . . . Choi, J. Deucravacitinib, an oral, selective, allosteric, tyrosine kinase 2 inhibitor, in patients with active SLE: Efficacy on patient-reported outcomes in a phase II randomised trial. BMJ Publishing Group.

Chicago Style (17th ed.) Citation

Arnaud, Laurent, et al. Deucravacitinib, an Oral, Selective, Allosteric, Tyrosine Kinase 2 Inhibitor, in Patients with Active SLE: Efficacy on Patient-reported Outcomes in a Phase II Randomised Trial. BMJ Publishing Group.

MLA (9th ed.) Citation

Arnaud, Laurent, et al. Deucravacitinib, an Oral, Selective, Allosteric, Tyrosine Kinase 2 Inhibitor, in Patients with Active SLE: Efficacy on Patient-reported Outcomes in a Phase II Randomised Trial. BMJ Publishing Group.